Regeneron (REGN) Tops Q2 EPS by 75c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. GOOGL
3. MSFT
4. ENPH
5. GOOG
6. HOOD
7. SPY
8. BA
9. NXPI
10. STX

Go back to Regeneron (REGN) Tops Q2 EPS by 75c

Regeneron Reports Second Quarter 2018 Financial and Operating Results

August 2, 2018 6:30 AM EDT

TARRYTOWN, N.Y., Aug. 2, 2018 /PRNewswire/ --

Second quarter 2018 GAAP net income per diluted share increased by 44% to $4.82 versus second quarter 2017 and second quarter 2018 non-GAAP net income per diluted share increased 31% to $5.45 versus second quarter 2017 Second quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 8% to $992 million versus second quarter 2017 and second quarter 2018 EYLEA global net sales(1) increased 13% to $1.66 billion versus second quarter 2017 Positive results reported from Phase 3 trial of Dupixent® (dupilumab) in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

Regeneron... More